Pfizer unveils Moodivator app to help patients monitor depression

Pfizer

Pfizer ($PFE) is going beyond the pill with its latest mental health offering. 

The pharma giant is out with a new app, dubbed Moodivator, which is meant to motivate people living with depression by encouraging them to do things like set goals, establish routines and identify mood patterns over time, Dr. Susan Kornstein, a professor of psychiatry at Virginia Commonwealth School of Medicine who consulted on the app's design, said in a statement. In that way, it helps "complement the treatment patients receive in a simple, efficient and portable way."

The app is not designed specifically to go along with any Pfizer medications--it can, in fact, be downloaded for free by anyone from the Apple iTunes Store--but it is meant as a meaningful solution for people with depression, Pfizer medical director Gustavo Rodriguez told FiercePharmaMarketing in an email interview.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

"Moodivator is Pfizer’s first app specifically designed for the millions of people in the United States who suffer from depression," he said. "The app was designed to help motivate and encourage patients with depression, helping them to take a more active role in their treatment."

Pfizer knows a thing or two about the malady. It markets multiple anti-depression drugs, including Zoloft and Pristiq. Other newer drugs in that category include Otsuka Pharmaceutical's Rexulti and Takeda Pharmaceutical's Brintellix.

But when the company saw survey data showing that 70% of patients being treated for a mental health disorder wanted mobile apps to be able to monitor their mental health daily, it knew it was time to add to its offerings.

Moodivator has benefits for Pfizer, too. The company can collect user data to "study, analyze and report on user experiences and results" with the app as well as use shared data "in an aggregate and/or anonymized format and may disclose such information to third parties for any purpose," according to the app's privacy statement.

- see Pfizer's release

Related Articles:
Pfizer escapes hundreds of lawsuits alleging birth defects tied to Zoloft
New Pfizer campaign has scientists stand up for the long and winding R&D road
IMS Health finds mHealth mobile app 'prescriptions' on the rise

Read more on

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.